KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received...

Related Keywords

Campbelltown ,New South Wales ,Australia ,New York ,United States ,Japan ,Cleveland ,Ohio ,Toronto ,Ontario ,Canada ,La Jolla ,California ,San Diego ,University Of California San Diego ,Howard University Hospital ,District Of Columbia ,Sydney ,Washington ,American ,Constance Katelaris ,Sandra Christiansen ,Stephen Betschel ,James Wedner ,Bob Geng ,Andrew Crockett ,Paula Busse ,American Academy Of Allergy ,Washington University School Of Medicine ,Division Of Clinical Immunology ,Department Of Medicine ,Division Of Allergy ,Exchange Commission ,Division Of Pediatric Allergy ,Sydney University ,University Hospitals Rainbow Babies ,Nasdaq ,University Of California ,University Of Toronto ,Kalvista Pharmaceuticals Inc ,Kalvista Pharmaceuticals ,Annual Meeting ,Poster Presentation ,On Demand Treatment ,Hereditary Angioedema Attacks ,Patient Perceptions ,Associated Barriers ,California San Diego ,Hereditary Angioedema ,Washington University School ,Refilling On Demand Therapy ,Treatment Delay ,Autumn Burnette ,Negative Impact ,Delayed On Demand Treatment ,Princess Ogbogu ,Pediatric Allergy ,Clinical Immunology ,Mount Sinai ,Patients With ,Prophylactic Treatment ,Patients Requiring Redosing ,On Demand Treatment After ,Campbelltown Hospital ,Western Sydney University ,Chief Executive Officer ,Vista Pharmaceuticals ,Securities Litigation Reform Act ,Markets ,